Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Business alliance4527ROHTO PHARMACEUTICAL CO.,LTD.
Alliance partnerファーマバイオ株式会社
Details of the alliance
- 1
Exclusive distribution in Japan
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionDevelopment and manufacturing of regenerative medicine products, contract development and manufacturing of regenerative medicine products, and other activities
LocationNishi-ku, Nagoya, Aichi Prefecture
Impact on Business Performance
The impact of this matter on the Company’s consolidated earnings forecast for the fiscal year ending March 2027 is expected to be immaterial.
| Item | Details |
|---|---|
| Name of alliance partner | ファーマバイオ株式会社 |
| Alliance partner's business activities | Development and manufacturing of regenerative medicine products, contract development and manufacturing of regenerative medicine products, and other activities |
| Alliance partner's location | Nishi-ku, Nagoya, Aichi Prefecture |
| Type of alliance | Business alliance |
| Details of the alliance | Exclusive distribution in Japan |
| Impact on Business Performance | The impact of this matter on the Company’s consolidated earnings forecast for the fiscal year ending March 2027 is expected to be immaterial. |
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To leverage the knowledge Rohto Pharmaceutical has developed in the ophthalmology field and, through collaboration with ファーマバイオ株式会社, advance efforts to provide a new treatment option for myopic chorioretinal atrophy.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.